Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation

KRAS mutation has been known as crucial marker for growth and maintenance of pancreatic cancer (PC) and targeting the KRAS is inevitable component for realizing precision medicine to PC. We established patient-derived tumor cells (PDCs) from patient with KRAS G12R mutant PC. Through the PDC, we inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Taehyang, Kim, Kyung, Lee, Jeeyun, Park, Se Hoon, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Park, Joon Oh, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160685/
https://www.ncbi.nlm.nih.gov/pubmed/30271501
http://dx.doi.org/10.7150/jca.26068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160685/
https://www.ncbi.nlm.nih.gov/pubmed/30271501
http://dx.doi.org/10.7150/jca.26068

Ejemplares similares